Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Cingulate Inc.

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
From Cingulate Inc.
Via GlobeNewswire
Tickers CING CINGW
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
From Cingulate Inc.
Via GlobeNewswire
Tickers CING CINGW
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
From Cingulate Inc.
Via GlobeNewswire
Tickers CING CINGW
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
From Cingulate Inc.
Via GlobeNewswire
Tickers CING CINGW
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
From Cingulate Inc.
Via GlobeNewswire
Tickers CING CINGW
Cingulate to Present at 13th Annual LD Micro Invitational
From Cingulate Inc.
Via GlobeNewswire
Tickers CING CINGW
Cingulate, Indegene to Participate in Benzinga All Live Access Event
From Cingulate Inc.
Via GlobeNewswire
Tickers CING CINGW
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
From Cingulate Inc.
Via GlobeNewswire
Tickers CING CINGW
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
From Cingulate Inc.
Via GlobeNewswire
Tickers CING CINGW SCTL
Cingulate to Participate in Benzinga All Live Access Event
From Cingulate Inc.
Via GlobeNewswire
Tickers CING CINGW
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
From Cingulate Inc.
Via GlobeNewswire
Tickers CING CINGW
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.